Podcasts about molecular

BUFFALO, NY – June 27, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights.” In this study, researchers led by first authors Cleto Dantas Nogueira from the Federal University of Ceará and Argos Pathology Laboratory and Samuel Frota from Argos Pathology Laboratory, along with corresponding author Fabio Tavora from the previously mentioned institutions and Messejana Heart and Lung Hospital, investigated how HER2 gene mutations appear in cases of non-small cell lung cancer (NSCLC) in Northeastern Brazil. The team found that HER2 mutations showed significant genetic diversity and were often associated with other cancer-related genetic changes. These findings revealed diagnostic and treatment challenges in a population that is rarely studied, emphasizing the need for expanded access to molecular testing and targeted therapies. HER2 mutations are a known factor in several cancers, including breast and gastric cancers. In lung cancer—particularly NSCLC—these mutations are less common but remain clinically significant. Most existing research on HER2-mutated lung cancer focuses on high-income countries, leaving important gaps in knowledge about underrepresented regions such as Latin America. This study helps fill that gap by analyzing 13 patients with HER2-mutated NSCLC using clinical, pathological, and genomic data. The patients ranged in age from 34 to 82 years, and more than half were women. About half had never smoked. Their tumors often displayed complex genetic profiles, including additional mutations in genes such as TP53, KRAS, and STK11. The most common HER2 mutation identified was an insertion in exon 20, a known hotspot for activating mutations. “Trastuzumab deruxtecan (T-DXd) is the first HER2-targeted agent to show clinical efficacy in HER2-mutant non-small cell lung cancer (HER2m NSCLC).” Treatment strategies among the patients varied. Only one individual received HER2-targeted therapy. Most were treated with surgery, chemotherapy, immunotherapy, or a combination of these approaches. Outcomes also differed, with some patients surviving for years and others dying within months of diagnosis. These findings reinforce the need for early diagnosis and improved access to advanced treatments, particularly in low-resource settings. The study emphasizes the value of comprehensive molecular profiling in NSCLC. Because HER2 mutations often occur alongside other genetic alterations, full genomic analysis is crucial for guiding treatment decisions. Yet, such testing is not always available. The researchers propose a tiered diagnostic approach, beginning with basic screening and expanding to more advanced tests when necessary, to enhance patient care. This study provides valuable insights into the molecular characteristics of HER2-mutated NSCLC in a Brazilian population, highlighting the complexity and clinical relevance of these alterations. Larger studies are needed to clarify the prevalence and prognostic significance of HER2 mutations, as well as their impact on treatment response and survival. This knowledge is essential for advancing effective HER2-targeted therapies. The findings also support broader implementation of international clinical guidelines in Latin America and highlight the critical need to include underrepresented populations in cancer research. DOI - https://doi.org/10.18632/oncotarget.28737 Correspondence to - Fabio Tavora - stellacpak@outlook.com Video short - https://www.youtube.com/watch?v=hr5R9iDBFFI To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

M

In einer Großstadt zu leben, kann herausfordernd sein: viel Beton und wenig Grün, viel Lärm und wenig Ruhe. Auch hier können wir einen Weg finden, Achtsamkeit zu praktizieren, indem wir uns ein Umfeld erschaffen, das guttut. **********An dieser Stelle findet ihr die Übung:00:32:02 - Geleitete Meditation für mehr Achtsamkeit im Großstadtleben**********Quellen aus der Folge:Adli, M., & Schöndorf, J. (2020). Macht uns die Stadt krank? Wirkung von Stadtstress auf Emotionen, Verhalten und psychische Gesundheit. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz, 63, 979-968.Hunter, M. R., Gillespie, B. W., & Chen, S. Y. P. (2019). Urban nature experiences reduce stress in the context of daily life based on salivary biomarkers. Front Psychol 10: 722.Lederbogen, F., Kirsch, P., Haddad, L., Streit, F., Tost, H., Schuch, P., ... & Meyer-Lindenberg, A. (2011). City living and urban upbringing affect neural social stress processing in humans. Nature, 474(7352), 498-501. Olszewska-Guizzo, A., Sia, A., Fogel, A., & Ho, R. (2022). Features of urban green spaces associated with positive emotions, mindfulness and relaxation. Scientific reports, 12(1), 20695.Sudimac, S., Sale, V., & Kühn, S. (2022). How nature nurtures: Amygdala activity decreases as the result of a one-hour walk in nature. Molecular psychiatry, 27(11), 4446-4452.**********Den Artikel zum Stück findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .**********Ihr habt Anregungen, Ideen, Themenwünsche? Dann schreibt uns gern unter achtsam@deutschlandfunknova.de

On This Week in HPC, Addison Snell and Doug Eadline prep for ISC25, take a look at Intersect360 Research's new forecast, and talk about the partnership between Meta and Berkeley Labs.

BUFFALO, NY – June 24, 2025 – A new precision #oncology paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.” In this report, led by Alberto Hernando-Calvo from Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology; Razelle Kurzrock from WIN Consortium and Medical College of Wisconsin; Oncotarget Editor-in-Chief Wafik S. El-Deiry from WIN Consortium and Legorreta Cancer Center at Brown University; and corresponding author Shai Magidi, also from WIN Consortium, along with colleagues, describe the case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. After analysis, the WIN International Molecular Tumor Board proposed different personalized treatment plans based on the tumor's unique genetic mutations. This case highlights the growing role of precision oncology in guiding therapies for patients with treatment-resistant cancers. Colorectal cancer is one of the deadliest cancers worldwide, and managing advanced cases remains a significant challenge. This patient had already received five prior treatment regimens, including chemotherapy and targeted therapies. Although some treatments were initially beneficial, the cancer eventually developed resistance. Molecular analysis revealed key mutations in genes such as BRAF, MET, APC, TP53, and NRAS, which are often linked to aggressive tumor behavior and reduced treatment effectiveness. With limited standard options left, the patient's case was presented and reviewed by the WIN International Molecular Tumor Board, a global panel of cancer experts. The team analyzed the clinical history and genetic profile to design new treatment approaches. These involved off-label drug combinations tailored to the specific mutations found in the tumor. For example, one approach combined trametinib, a drug that blocks cancer cell growth signals, with amivantamab, an antibody that attacks cancer-related proteins MET and EGFR, and regorafenib, which helps cut off blood supply to tumors and may counteract effects from APC and TP53 mutations. “Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily.” This case reflects a shift in cancer care from standardized protocols to precision approaches, where therapy is selected based on a tumor's molecular features. Such strategies aim to delay resistance and slow disease progression more effectively. The WIN International Molecular Tumor Board also discussed practical challenges, including access to medications, combining off-label drugs, and the difficulties of enrolling patients in clinical trials after multiple prior treatments. Although the ultimate treatment decision remained with the patient's physician, this report shows how international collaboration and precision oncology can expand options for patients facing limited alternatives. It also emphasizes the value of repeat genetic analysis during disease progression to monitor new mutations in the tumor that may impact treatment. While the patient ultimately died from cancer progression, this case serves as a model for how molecular analysis and expert input can be used to guide treatment even in complex and metastatic colorectal cancer. As personalized cancer strategies continue to evolve, they may offer potential pathways for patients who have exhausted standard treatment options. DOI - https://doi.org/10.18632/oncotarget.28744 Correspondence to - Shai Magidi - shai.magidi@winconsortium.org Video short - https://www.youtube.com/watch?v=uWDtWNgpK7A To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

*This episode was originally released in March 2022*For some inspiring summer listening, we are re-sharing some of our favorite episodes on the power of science and chemistry. This is the VERY FIRST episode we released. Stay tuned for our next season featuring our customers and partners starting in September!In this episode, first released in March 2022, Ilham sits down with Nobel prize-winning scientists Professor Steven Chu and Professor Ben Feringa to discuss some of the most exciting innovations in energy, clean mobility, and healthcare; the importance of ensuring that scientific innovation is at the service of humanity; the winner of the 2022 Ernest Solvay Prize by Syensqo; and how science and chemistry are key to enabling a more sustainable future.  Steven Chu is a professor of Molecular and Cellular Physiology at Stanford University and the former US Secretary of Energy. In 1997, he was awarded the Nobel Prize in Physics for developing methods to cool and trap atoms with laser lights. Ben Feringa is a Professor at the University of Groningen, and the winner of the 2015 Solvay prize. In 2016, he won the Nobel Prize in Chemistry for his groundbreaking research on the design and synthesis of molecular machines. They were both part of the jury that chose the winner for the 2022 Ernest Solvay Prize by Syensqo, Katalin Karikó.  For additional details about the podcast, show notes, and access to resources mentioned during the show, please visit https://www.syensqo.com/en/podcast

Drs Kaniksha Desai and Jennifer Sipos discuss molecular marker testing in the evaluation of thyroid nodules. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/index/list_15483_0

Imagine destroying cancer cells with nothing but a common hospital dye and a beam oflight. Researchers at Rice University have unveiled a revolutionary treatment that uses aspecial light to trigger violent vibrations in cancer cells, tearing them apart from the insidewith 99% efficiency in lab trials. Dubbed ‘molecular jackhammers,' this method couldspare millions from chemo's brutal side effects and target everything from melanoma tobreast cancer.Dr. Bob and Dr. Brockman take calls and emails from listeners

Why is the universe the way it is? Wherever we look, we find ordered structures: from stars to planets to living cells. Molecular Storms: The Physics of Stars, Cells and the Origin of Life (Springer Nature, 2023) shows that the same driving force is behind structure everywhere: the incessant random motion of the components of matter. Physicists call it thermal noise. Let's call it the molecular storm. This storm drives the fusion reactions that make stars shine. It drives whirlpools and currents in atmospheres and oceans. It spins and distorts molecules until they are in the right orientation to react and form new substances. In living cells, it drives proteins to fold and molecules to self-assemble. It is behind every detail of the astonishing molecular machines that control cellular processes. Using cutting-edge research, "Molecular Storms" takes us on a dazzling journey from the early universe to the interior of the smallest living things. There, in a nanoscale world of biological devices, it explains the physics behind the chemical system which we call Life. Whether you're someone with a general interest in science or a student looking to add context to your studies, this book is for you. "Molecular Storms" is an accessible and captivating read that will deepen your appreciation of the power of science to explain the world. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Why is the universe the way it is? Wherever we look, we find ordered structures: from stars to planets to living cells. Molecular Storms: The Physics of Stars, Cells and the Origin of Life (Springer Nature, 2023) shows that the same driving force is behind structure everywhere: the incessant random motion of the components of matter. Physicists call it thermal noise. Let's call it the molecular storm. This storm drives the fusion reactions that make stars shine. It drives whirlpools and currents in atmospheres and oceans. It spins and distorts molecules until they are in the right orientation to react and form new substances. In living cells, it drives proteins to fold and molecules to self-assemble. It is behind every detail of the astonishing molecular machines that control cellular processes. Using cutting-edge research, "Molecular Storms" takes us on a dazzling journey from the early universe to the interior of the smallest living things. There, in a nanoscale world of biological devices, it explains the physics behind the chemical system which we call Life. Whether you're someone with a general interest in science or a student looking to add context to your studies, this book is for you. "Molecular Storms" is an accessible and captivating read that will deepen your appreciation of the power of science to explain the world. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science

Why is the universe the way it is? Wherever we look, we find ordered structures: from stars to planets to living cells. Molecular Storms: The Physics of Stars, Cells and the Origin of Life (Springer Nature, 2023) shows that the same driving force is behind structure everywhere: the incessant random motion of the components of matter. Physicists call it thermal noise. Let's call it the molecular storm. This storm drives the fusion reactions that make stars shine. It drives whirlpools and currents in atmospheres and oceans. It spins and distorts molecules until they are in the right orientation to react and form new substances. In living cells, it drives proteins to fold and molecules to self-assemble. It is behind every detail of the astonishing molecular machines that control cellular processes. Using cutting-edge research, "Molecular Storms" takes us on a dazzling journey from the early universe to the interior of the smallest living things. There, in a nanoscale world of biological devices, it explains the physics behind the chemical system which we call Life. Whether you're someone with a general interest in science or a student looking to add context to your studies, this book is for you. "Molecular Storms" is an accessible and captivating read that will deepen your appreciation of the power of science to explain the world. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Pablo Gravina (Jefe de Clínica, Bioquímico del Laboratorio de Biología Molecular-Genética, Representante de la Asociación de Profesionales y Técnicos del Hospital Garrahan) La Usina

Scientific discovery often unfolds in unexpected ways. What begins as a search for solutions to real-world challenges can lead researchers into unexplored scientific territory, where unconventional ideas emerge and spark debate. This dynamic was at the heart of research by Dr. Arthur W. Snow and Dr. Ramagopal Ananth in the Chemistry Division of the US Naval Research Laboratory. Their study aimed to address a pressing need: replacing fluorocarbon surfactants in firefighting foams. What they discovered would take them beyond firefighting applications and into fundamental questions about the nature of water itself.

Seth Diehl, our newest Ortho rep, joins me today to walk us through what makes the Ortho Molecular products exceptionally high quality and why they are our top choice. He explains how Ortho Molecular Products is the only remaining practitioner and supplement manufacturer and the only company that has not sold out. We also dive into our latest products, Choline Support, L-Theanine, Inositol Complex, Estro Support, Milk Thistle, and Neuro Support Magnesium. The benefits of combining L-Theanine with your morning coffee: It reduces the jittery caffeine excitement  It provides a relaxed energy boost It supports GABA, the most calming neurotransmitter Seth Diehl's Bio: Seth Diehl is an Account Executive with Ortho Molecular Products, proudly supporting healthcare practitioners throughout Iowa, including myself and the exceptional team at Integrative Health and Hormone Clinic.  Seth earned both his Bachelor's in Biology and Master's in Biomedical Sciences from Iowa State University. Initially unfamiliar with integrative and functional medicine, Seth quickly became an enthusiastic advocate after discovering the impactful role preventative approaches play in overall health.  Today, he combines his scientific expertise with a genuine passion for wellness, providing healthcare professionals with tailored health solutions and proactive patient care strategies. Seth feels privileged to collaborate with practitioners across his home state, backed by an organization that supports the transformation of the practice of medicine alongside integrative and functional medicine providers nationwide. In this episode: What differentiates Ortho Molecular Products from the rest, making them the best supplement manufacturer? How they use trademarked and patented raw materials throughout their product lines to ensure therapeutic outcomes Why you need to be careful when following the advice of influencers on social media- especially those with no background in healthcare  How Ortho Molecular Products safeguards its manufacturing processes by adhering to FDA regulations for its food and pharmaceutical products  How Choline Support supports cellular and mitochondrial membranes for better brain health and more energy How L-Theanine reduces stress and promotes relaxation without causing drowsiness How the unique form of magnesium in Neuro Magnesium Support improves sleep quality and memory and reduces brain fog How our new product, Inositol Complex, can be used to address the symptoms of PCOS How Estro Support helps women manage their menopause symptoms How Milk Thistle aids liver detoxification Links and Resources: Use code ENERGY to get 10% off ⁠⁠MITOCHONDRIAL COMPLEX Use code TURMERIC to get 10% off ⁠⁠TURMERIC Try Halo (Salt) Therapy for respiratory and skin health. Call 319-363-0033 to schedule your session. Relative Links for This Show: Neuro Magnesium Support  L-Theanine – 60 capsules Use code PODCAST for 10% off your next supplement purchase  Inositol Complex Choline Support EstroSupport Follow Your Longevity Blueprint  On Instagram| Facebook| Twitter| YouTube | LinkedIn Get your copy of the Your Longevity Blueprint book and claim your bonuses here Find Dr. Stephanie Gray and Your Longevity Blueprint online   Follow Dr. Stephanie Gray  On Facebook| Instagram| Youtube | Twitter | LinkedIn Integrative Health and Hormone Clinic Podcast production by Team Podcast

Stephen Wolfram answers questions from his viewers about the future of science and technology as part of an unscripted livestream series, also available on YouTube here: https://wolfr.am/youtube-sw-qaTopics discussed: The limits and future of software defined everything - Molecular design and biological engineering - Human enhancement and genome level modification

About Eric Betzig:Eric Betzig is a Professor of Molecular and Cell Biology at UC Berkeley, holding the Eugene D. Commins Presidential Chair in Experimental Physics. He is also a Senior Fellow at the Janelia Research Campus and an Investigator of the Howard Hughes Medical Institute. After earning his Ph.D. at Cornell and working at AT&T Bell Labs on near-field optics, he left academia in 1995 for the machine tool industry. He returned to science in 2005, building the first super-resolution single molecule localization microscope with Harald Hess, work that earned him the 2014 Nobel Prize in Chemistry. Today, he develops advanced microscopy techniques for biological discovery, including correlative super-resolution fluorescence and electron microscopy, and 4D dynamic imaging of living systems.About Gita Wirjawan:Gita is an Indonesian entrepreneur and educator. He is the founding partner of Ikhlas Capital and the chairman of Ancora Group. Currently, he is teaching at Stanford as a Visiting Scholar at the Shorenstein Asia-Pacific Research Center (APARC); and a fellow at the Harvard Kennedy School's Belfer Center for Science and International Affairs.Explore this episode and be part of our communityhttps://endgame.id/Collaborations and partnershipshttps://sgpp.me/contactus

An awe-inspiring journey into the world of proteins--how they shape life, and their remarkable potential to heal our bodies and our planet. Each fall, a robin begins the long trek north from Gibraltar to her summer home in Central Europe. Nestled deep in her optic nerve, a tiny protein turns a lone electron into a compass, allowing her to see north in colors we can only dream of perceiving. Taking us beyond the confines of our own experiences, The Color of North: The Molecular Language of Proteins and the Future of Life (Belknap Press, 2025) traverses the kingdom of life to uncover the myriad ways that proteins shape us and all organisms on the planet. Inside every cell, a tight-knit community of millions of proteins skillfully contorts into unique shapes to give fireflies their ghostly glow, enable the octopus to see predators with its skin, and make humans fall in love. Collectively, proteins orchestrate the intricate relationships within ecosystems and forge the trajectory of life. And yet, nature has exploited just a fraction of their immense potential. Shahir S. Rizk and Maggie M. Fink show how breathtaking advances in protein engineering are expanding on nature's repertoire, introducing proteins that can detect environmental pollutants, capture carbon dioxide from the atmosphere, and treat diseases from cancer to COVID-19. Weaving together themes of memory, migration, and family with cutting-edge research, The Color of North unveils a molecular world in which proteins are the pulsing heart of life. Ultimately, we gain a new appreciation for our intimate connections to the world around us and a deeper understanding of ourselves. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Sergio Perera is a chef & nutrition expert. Having trained as a professional chef in some of Spain's most respected restaurants and then training in Japan, a serendipitous moment saw Sergio become the go to private chef to Hollywood actors (such as Tom Cruise, Robert Downey Jr, Leonardo DiCaprio, Chris Hemsworth), athletes, royalty and politicians. Growing up in Spain he was naturally an advocate for the healthy Mediterranean diet, but it was working with actors which prompted him to study and learn more about nutrition and during his time with Chris Hemsworth he helped prepare him for the role Thor, optimising his nutrition to support his exercise and muscle building regime. He was an integral part of the successful training app known as CENTR by Chris Hemsworth, writing recipes, diet programs and meditations, offering subscribers a holistic wellness approach. Sergio has an international upbringing, born in Spain to a Mexican/American and Spanish Parents and growing up on a US Airforce base, has given Sergio a unique perspective on food and culture. Sergio's love for food and cooking began in his Grandfather's kitchen where he learnt the traditional cuisine of the Aragon region. At the age of 18, he set off to expand his repertoire of Spanish cuisine by training at some of the world's most prestigious restaurants such as ARZAK, Mugaritz and with Albert Adria at the iconic el Bulli restaurant in Roses, Spain. His curiosity and passion for culture eventually lead him to Kyoto, Japan where he was introduced to Kaiseki which is an exquisite form of dining that moves elegantly and poetically with the seasons.  Sergio has used his culinary and artistic experience to create beautiful and inspirational images for food books, magazines and film productions. He is currently the brand ambassador for Winning Appliances, working alongside John Winning's team on numerous culinary and creative projects. The most recent has been the opening of ORA Japanese dining and bar in Sydney's Waterloo. Always eager to embrace new opportunities, Sergio welcomes the chance to work with clients—whether they are actors preparing for a film, high-profile individuals seeking an exclusive private dinner, or those planning a special event. He has also trained numerous chefs in becoming the ultimate private chef/nutritionist for high profile families and individuals and has been creating a small team of elite chefs throughout Australia. He actively participates in restaurant consultations across Australia, Europe, and the U.S., ensuring that each culinary experience is tailored to meet the unique needs of his clients. We chat about his life changing time in Japan, intuition, mindfulness, living in his car, creativity and food, flow, Molecular gastronomy and working with the masters, the new chef, vulnerability, moving to Australia and working with Chris Hemsworth, love of music, fear, and of course food plus plenty more! Check Sergio out on: Instagram: https://www.instagram.com/sergio.perera Website: https://www.pererasergio.com/ ------------------------------------------- Follow @Funny in Failure on Instagram and Facebook https://www.instagram.com/funnyinfailure/ https://www.facebook.com/funnyinfailure/ and @Michael_Kahan on Insta & Twitter to keep up to date with the latest info. https://www.instagram.com/michael_kahan/ https://twitter.com/Michael_Kahan

An awe-inspiring journey into the world of proteins--how they shape life, and their remarkable potential to heal our bodies and our planet. Each fall, a robin begins the long trek north from Gibraltar to her summer home in Central Europe. Nestled deep in her optic nerve, a tiny protein turns a lone electron into a compass, allowing her to see north in colors we can only dream of perceiving. Taking us beyond the confines of our own experiences, The Color of North: The Molecular Language of Proteins and the Future of Life (Belknap Press, 2025) traverses the kingdom of life to uncover the myriad ways that proteins shape us and all organisms on the planet. Inside every cell, a tight-knit community of millions of proteins skillfully contorts into unique shapes to give fireflies their ghostly glow, enable the octopus to see predators with its skin, and make humans fall in love. Collectively, proteins orchestrate the intricate relationships within ecosystems and forge the trajectory of life. And yet, nature has exploited just a fraction of their immense potential. Shahir S. Rizk and Maggie M. Fink show how breathtaking advances in protein engineering are expanding on nature's repertoire, introducing proteins that can detect environmental pollutants, capture carbon dioxide from the atmosphere, and treat diseases from cancer to COVID-19. Weaving together themes of memory, migration, and family with cutting-edge research, The Color of North unveils a molecular world in which proteins are the pulsing heart of life. Ultimately, we gain a new appreciation for our intimate connections to the world around us and a deeper understanding of ourselves. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science

An awe-inspiring journey into the world of proteins--how they shape life, and their remarkable potential to heal our bodies and our planet. Each fall, a robin begins the long trek north from Gibraltar to her summer home in Central Europe. Nestled deep in her optic nerve, a tiny protein turns a lone electron into a compass, allowing her to see north in colors we can only dream of perceiving. Taking us beyond the confines of our own experiences, The Color of North: The Molecular Language of Proteins and the Future of Life (Belknap Press, 2025) traverses the kingdom of life to uncover the myriad ways that proteins shape us and all organisms on the planet. Inside every cell, a tight-knit community of millions of proteins skillfully contorts into unique shapes to give fireflies their ghostly glow, enable the octopus to see predators with its skin, and make humans fall in love. Collectively, proteins orchestrate the intricate relationships within ecosystems and forge the trajectory of life. And yet, nature has exploited just a fraction of their immense potential. Shahir S. Rizk and Maggie M. Fink show how breathtaking advances in protein engineering are expanding on nature's repertoire, introducing proteins that can detect environmental pollutants, capture carbon dioxide from the atmosphere, and treat diseases from cancer to COVID-19. Weaving together themes of memory, migration, and family with cutting-edge research, The Color of North unveils a molecular world in which proteins are the pulsing heart of life. Ultimately, we gain a new appreciation for our intimate connections to the world around us and a deeper understanding of ourselves. Learn more about your ad choices. Visit megaphone.fm/adchoices

The creation of a landmark gene editing drug used to treat a baby with a rare genetic mutation which could help transform personalized medicine. Blood tests showed baby KJ had sky-high levels of ammonia, a toxic substance the body usually expels. The root cause was his genes - or more particularly a specific gene mutation. The race was on to try and treat him before his condition took a firm hold. His doctors came up with a radical solution - for the first time ever, they designed and applied a gene-editing drug in record time, specifically for him. Have we seen breakthrough in preventing genetic diseases? With Fyodor Urnov, a professor in the Molecular and Cell Biology Department at the University of California, Virginijus Šikšnys professor at the Life Science Center of Vilnius University, Waseem Qasim from the UCL Institute of Child Health in Great Ormond Street Hospital in London and Jennifer Doudna, Professor, University of California, Berkeley and founder of the Innovative Genomics Institute. Presented by Tanya Beckett. Produced by Bob Howard. Researched by Mauve Schaffer Edited by Tara McDermott.

In the second part of this special episode of Onc Now, Jonathan Sackier continues his thrilling conversation with Bradley Monk, a leading gynaecologic oncologist, with an in-depth discussion of the DUO-E trial, Monk's most impactful Society of Gynecologic Oncology (SGO) insights, and the integration of AI into the clinic. Timestamps:  00:00 – Introduction  00:40 – Quickfire questions  06:19 – Inspiration  08:31 – Molecular basis of cancer treatment  12:12 – DUO-E trial design  14:12 – Barriers to 4-drug regimen approval and access  20:01 – Most impactful SGO insights  21:10 – AI integration  24:03 – Three wishes  26:30 – Outro 

Hello Fam, Due to some changes in policies in streaming platforms like Spotify, we would be changing our Sleep Music only content to Guided Meditation + Sleep Music to help you sleep better. As uploading Music Only Tracks would make the Spotify remove our Podcast, so that's the reason for changing To Guided Meditation Tracks. We will also be coming soon with our own Android/iOS app to serve you better. Hope you understand and continue to support us. Regards, The Mindset Meditation Team Don't Click This: https://bit.ly/2RnSdjS Follow us on Instagram: https://instagram.com/themindsetmeditationpodcast?igshid=YmMyMTA2M2Y= Rainbow Road Binaural Molecular Stimulation Guided Meditation Detox your mind and heart of thoughts and emotions that don´t serve you anymore, but are there out of habit. Close your eyes, take a minimum of six slow deep breaths, and begin focusing on relaxing every inch of your body. - Start by focusing on your toes and wiggle and relax your toes - Relax your feet, rotate your ankles and relax your feet - Work up to your calves, Relax your muscles - Continue working your way up your body, one body part at a time. Within minutes as you work your way up to your head continue to take deep breaths. You will begin to feel relaxed as if you were floating. Your body and brain will be massaged into a deep sleep. Detach and let go. Feel at peace. Feel happy. Feel Free. Don't forget it may be useful for your family and friends too. Enjoy this amazing episode. Don't forget to Subscribe to our YouTube channel: The Mindset Meditation Link to our YouTube channel: https://bit.ly/2RnSdjS

Divulgação de Cura Biológica, Imunológica e Molecular - ACRS with Eleana

AGNTCY - Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support. What if your blood could reveal the future of your health - years before symptoms ever appear? In this episode of Eye on AI, Craig Smith sits down with Ash Anwar, co-founder of Molecular You, to explore how AI and advanced biomarker analysis are transforming how we detect and prevent disease.  From a real-life case where stage 1 pancreatic cancer was caught early, to the science behind tracking 250+ dynamic biomarkers, Ash breaks down how Molecular You is shifting healthcare from reactive treatment to proactive longevity.  They dive into the limitations of genetic testing, the power of machine learning models trained on clinical data, and how personalized action plans are helping individuals take control of their health in real time.  If you're curious about the intersection of AI, diagnostics, and the future of preventive medicine—this is a conversation you won't want to miss. Stay Updated: Craig Smith on X: https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI (00:00) How AI Can Predict Disease Before It Happens   (02:02) Meet Ash Anwar: From Scientist to Health Tech Leader   (06:31) What Is Molecular You and How It Works   (09:43) Why Biomarker Tracking Over Time Is a Game-Changer   (15:46) How Molecular You Detected Stage 1 Pancreatic Cancer   (23:15) Biomarkers vs Genetics: What Really Matters   (28:11) The AI Models Behind Early Disease Detection   (32:37) How the Product Works for Clinics and Consumers   (35:05) Who They Compete With and What Makes Them Different   (37:34) Research vs Product: The Cancer Risk Challenge   (43:43) How Often Should You Get Tested?

La biofísica española Eva Nogales, catedrática de Biología Molecular en la Universidad de Berkeley, ha sido la primera española en ganar el Premio Shaw y suena en las quinielas para el Nobel, aunque no le guste demasiado oírlo. Es líder mundial en el estudio de la expresión genética y la fotografía atómica de las células. Está convencida de que conocer, átomo a átomo, de qué estamos hechos va a revolucionarlo todo: "este es nuestro siglo".

Welcome to a brand new episode of Beyond the Thesis with Papa PhD! In this conversation, host David Mendes sits down with Dr. Colleen Kelly, a seasoned chemistry professor, researcher, and now award-winning author of children's chemistry comic books. With a PhD in chemistry from Penn State, Colleen's career has spanned environmental toxicology, medicinal chemistry, and decades of teaching at the University of Arizona. But it's her mission to transform “molecular literacy” for learners ages eight to one hundred and eight that sets her apart. Inspired by her own educational journey as a first-generation college student and by watching her students struggle with the basics of chemistry, Colleen shares how she's harnessing the power of stories and comics to make the foundational elements of science accessible—and fun—for kids (and adults!). In this episode, you'll hear about Colleen's personal path from student to researcher to educator, her realization that many students hit a wall due to “molecular illiteracy,” and her bold decision to bring chemistry alive through colorful storytelling. We'll explore how she draws on pop culture, imagination, and even comic book heroes to help students of all ages see and understand the science around them. You'll also get a peek at her Emmy-winning PBS documentary, Comic Book Chemistry, and her growing collection of educational comic adventures. Whether you're a scientist, an educator, a parent, or just someone who wants to see more people excited about science, this episode is packed with inspiration, practical insights, and heartwarming stories of curiosity, resilience, and the lifelong power of learning.   Creating fun and accessible chemistry stories has been a labor of love for Colleen as a retired University of Arizona chemistry professor and author of a series of kid's chemistry comic books. In 2023, the PBS short documentary, “Comic Book Chemistry” was awarded an Emmy. This documentary centered around Colleen's vision, chemistry comic book series and her success with teaching college-level chemistry concepts to kids. This vision was then presented as a TEDx talk, “Molecular Literacy for Ages 8 – 108” in 2025. During Colleen's 30 years of teaching chemistry, she became aware that her students were struggling with basic concepts, including fluency with the symbols for the elements themselves. These comic books, videos, and activities are Colleen's gift to all future scientists – one that will help them succeed in college chemistry. Colleen holds a Ph.D. in chemistry from Penn State University, was awarded a Chateaubriand Fellowship to conduct research at the Universite Pasteur in Strasbourg, France under the direction of Nobel Prize Winner, Jean-Marie Lehn. Colleen was a tenured faculty member with research expertise in environmental toxicology, medicinal chemistry, and chemistry education. She has published four chemistry textbooks, over 30 peer-reviewed articles, and has presented her work globally. What we covered in the interview:  Early Foundations Matter: Dr. Kelley argues for introducing the “alphabet of science” (the periodic table) to kids as young as 8, when their brains are wired to associate symbols with meaning – just like learning to read or play music.  Storytelling Changes Everything: By turning molecules into characters and chemistry lessons into narratives, students remember and see the science, rather than just memorize it.  Literacy Beyond Academics: Chemistry literacy empowers everyone, from future doctors to curious consumers, to make informed decisions about medicine, the environment, and everyday life. Science is a language everyone deserves to speak.  Whether you're eyeing your first job outside academia or aiming to grow within an organization, this episode has advice you can act on today! See the resources section below for Rob Lion's links! This episode's resources: Website: KidsChemicalSolutions.com Thank you, Colleen Kelley! If you enjoyed this conversation with Colleen, let her know by clicking the link below and leaving her a message on Linkedin: Send Colleen Kelley a thank you message on Linkedin! Click here to share your key take-away from this interview with David! Leave a review on Podchaser ! Support the show !   You might also like the following episodes: Sarah McLusky – Research Adjacent Podcast Collab Sara Thompson – Four Practices You Must Learn From Gig Workers Rayana Luna –Navigating Medical Affairs Careers Sylvie Lahaie – Navigating Stress and Anxiety in Graduate School

Steve Grzanich has the business news of the day with the Wintrust Business Minute. The University of Chicago has received a $21 million donation to establish a new quantum research center. Philanthropist Thea Berggren made the donation, and the new center will include her name. It’ll will be located in the Pritzker School of Molecular […]

Die Amygdala ist unser Angstzentrum. Viele kennen sie auch als "Mandelkern". Diese Amygdala schrumpft und wächst, je nachdem, wie wir unser Gehirn benutzen. Und wir haben Einfluss darauf. **********Quellen aus der Folge:Maher, C., Tortolero, L., Jun, S., Cummins, D. D., Saad, A., Young, J., ... & Saez, I. (2025). Intracranial substrates of meditation-induced neuromodulation in the amygdala and hippocampus. Proceedings of the National Academy of Sciences, 122(6), e2409423122.Sato, W., Kochiyama, T., Uono, S., Sawada, R., & Yoshikawa, S. (2020). Amygdala activity related to perceived social support. Scientific Reports, 10(1), 2951. Sudimac, S., Sale, V., & Kühn, S. (2022).How nature nurtures: Amygdala activity decreases as the result of a one-hour walk in nature. Molecular psychiatry, 27(11), 4446-4452. Van Der Helm, E., Yao, J., Dutt, S., Rao, V., Saletin, J. M., & Walker, M. P. (2011). REM sleep depotentiates amygdala activity to previous emotional experiences. Current biology, 21(23), 2029-2023**********Mehr zum Thema bei Deutschlandfunk Nova:Neurowissenschaften: Was im Hirn passiert, wenn wir Angst habenWarum sich stressige Erlebnisse in unser Gehirn einbrennenNeurowissenschaften: Das Gehirn trainieren**********Den Artikel zum Stück findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .**********Ihr habt Anregungen, Ideen, Themenwünsche? Dann schreibt uns gern unter achtsam@deutschlandfunknova.de

Feel like your body's no longer responding the way it used to—despite doing everything “right”? In this episode, we're diving into the world of bioactive peptides: what they are, how they work, and why they're becoming a game changer for women over 35 dealing with fatigue, muscle loss, inflammation, and hormone shifts. We break down the science behind Make Wellness peptides and how they help your body heal, rebuild, and thrive from the inside out.   Hosted by Leanne Vogel.   Coaching and other supports available at: https://shop.healthfulpursuit.com/    Podcast Sponsors, links and offers available at: https://www.healthfulpursuit.com/podcast/  Bioactive Peptides: https://www.healthfulpursuit.com/make 

Explore the expanding role of artificial intelligence (AI) in scientific discovery, with a focus on early-stage molecular design and synthesis. Uncover an overview of recent advancements in AI applications that are shaping how we approach molecular discovery—highlighting both their transformative potential and the important considerations around dual-use implications.Join Soc(AI)ety Seminars as we host Connor Coley, the Class of 1957 Career Development Professor and Associate Professor in the Department of Electrical Engineering and Computer Science at MIT.Thanks for listening! The ThinkND Podcast is brought to you by ThinkND, the University of Notre Dame's online learning community. We connect you with videos, podcasts, articles, courses, and other resources to inspire minds and spark conversations on topics that matter to you — everything from faith and politics, to science, technology, and your career. Learn more about ThinkND and register for upcoming live events at think.nd.edu. Join our LinkedIn community for updates, episode clips, and more.

Artificial intelligence is reshaping our world – but what does that mean for healthcare, scientific discovery, and human potential? In Genesis: Artificial Intelligence, Hope, and the Human Spirit, co-authors Craig Mundie, Henry Kissinger, and Eric Schmidt explore the profound implications of AI on society. In this collaborative event between Town Hall Seattle and the Institute for Systems Biology (ISB), Craig Mundie joins Dr. Jim Heath, President of ISB, for a thought-provoking conversation about the future of AI. They will discuss insights from the book, the opportunities and challenges AI presents, and what it means for the way we live, work, and care for our health. Co-author, Genesis: Artificial Intelligence, Hope, and the Human Spirit, Craig Mundie is a leading technology executive and former Chief Research and Strategy Officer at Microsoft. Over his decades-long career, he has played a pivotal role in advancing artificial intelligence, computing, and national security initiatives. Alongside Henry Kissinger and Eric Schmidt, he co-authored Genesis, a deep exploration of AI's impact on society and the future of humanity. Mundie has served as an advisor to the U.S. government on technology policy and was a member of the President's Council of Advisors on Science and Technology. President and Professor, Institute for Systems Biology (ISB) Dr. Jim Heath is a pioneering scientist in systems biology, cancer research, and precision medicine. Since 2018, he has led ISB, driving interdisciplinary research in cancer and immune system dynamics while advancing innovative approaches to complex diseases. An internationally recognized scientist, Heath has received numerous honors, including the Irving Weinstein Award from the American Association for Cancer Research and the Sackler Prize in the Physical Sciences. Before ISB, he was the Elizabeth W. Gilloon Professor of Chemistry at Caltech and a Professor of Molecular and Medical Pharmacology at UCLA. Presented by Town Hall Seattle and Institute for Systems Biology. Buy the Book Genesis: Artificial Intelligence, Hope, and the Human Spirit Elliott Bay Book Company

OsteoBites welcomes Yingqi Hua, MD from Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine to discuss his work on molecular subtyping of osteosarcoma, ecDNA, and more.Dr. Hua has been engaged in basic and clinical research of malignant bone tumors for more than 10 years, focusing on the individualized comprehensive treatment of advanced bone tumors, and is committed to transforming research results through clinical research. His research interests include 1. Multi-omics study of osteosarcoma: Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. 2. Epigenetic study of bone tumors: the function of histone mutation and the function of different histone methylation modification. 3. Drug screen: Screening sensitive drugs by patient derived xenograft(PDX) and explore the mechanism of drug action. 4. Clinical trial of advanced stage sarcomas based on precision medicine.

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

Welcome to the podcast with Dr. Brendan McCarthy!   This episode takes you deep into the real-world practice of prescribing testosterone therapy for women. This is not a high-level overview—this is a nuts and bolts breakdown: ✅ Who it's for ✅ How it's dosed ✅ What labs to run ✅ What delivery methods are safest ✅ Why it's often done wrong—and how to get it right   With over 20 years of clinical experience, Dr. McCarthy shares the insights no seminar or textbook can offer, including the emotional and psychological challenges women face when beginning testosterone therapy, and the very real fears around side effects and community stigma.  

Drs Park and Malla began by talking through the clinical utility of ctDNA in patients with stage II and III colon cancer. Dr Malla referenced the DYNAMIC (ACTRN12615000381583) and observational BESPOKE CRC (NCT04264702) trials, noting that ctDNA serves as a prognostic biomarker for recurrence and is increasingly used to guide post-surgical surveillance.

El catedrático de Bioquímica y Biología Molecular en la Universidad de Oviedo Carlos López-Otín es entrevistado por Ramón González Férriz en una nueva sesión de Memorias de la Fundación, cuyos protagonistas son destacadas personalidades provenientes de diferentes ámbitos de la cultura que fueron destinatarios de becas o ayudas de la Fundación Juan March. Fue merecedor de una beca de investigación de la Fundación Juan March en 1988 con la que presentó la memoria titulada Microsecuenciación de proteínas: aplicación al estudio de proteínas implicadas en demencia senil y enfermedades relacionadas. Es miembro de la Academia Europea y de la Real Academia de Ciencias de España. Ha publicado más de trescientos artículos en prestigiosas revistas internacionales, y también desarrolla una destacada labor como ensayista, con libros como La vida en cuatro letras, El sueño del tiempo, con Guido Kroemer, y Egoístas, inmortales y viajeras. Su título más reciente es La levedad de las libélulas (2024).Más información de este acto

Welcome to the podcast with Dr. Brendan McCarthy!   In this episode we dive deep into one of the most misunderstood and debated topics in hormone health: testosterone replacement therapy (TRT) for women. You may have heard horror stories—or glowing reviews. But what's the truth? Dr. McCarthy discusses: - Why testosterone matters for women's health - How it affects brain chemistry, mood, bone density, and even breast tissue - Its role after estrogen-suppressing breast cancer treatments - The difference between safe and unsafe TRT - What your provider should be doing to monitor and manage it effectively   Dr. Brendan McCarthy founded Protea Medical Center in 2002. While he's been the chief medical officer, Protea has grown and evolved into a dynamic medical center serving the Valley and Central Arizona. A nationally recognized as an expert in hormone replacement therapy, Dr McCarthy s the only instructor in the nation who teaches BioHRT on live patients. Physicians travel to Arizona to take his course and integrate it into their own practices. Besides hormone replacement therapy, Dr. McCarthy has spoken nationally and locally before physicians on topics such as weight loss, infertility, nutritional therapy and more.   Citations: Popma, Arne, et al. "Cortisol moderates the relationship between testosterone and aggression in delinquent male adolescents." Biological psychiatry 61.3 (2007): 405-411 Likhtik, E., Stujenske, J. M., Topiwala, M. A., Harris, A. Z. & Gordon, J. A. Prefrontal entrainment of amygdala activity signals safety in learned fear and innate anxiety. Nat. Neurosci. 17, 106–113 (2014). Brannon, Skylar M., et al. "Exogenous testosterone increases sensitivity to moral norms in moral dilemma judgements." Nature Human Behaviour 3.8 (2019): 856-866.. * M.H.M. Hutschemaekers, R.A. de Kleine, M.L. Davis, M. Kampman, J.A.J. Smits, K. Roelofs,Endogenous testosterone levels are predictive of symptom reduction with exposure therapy in social anxiety disorder,Psychoneuroendocrinology,Volume 115,2020,104612 Barel, E, Abu‐Shkara, R, Colodner, R, et al. Gonadal hormones modulate the HPA‐axis and the SNS in response to psychosocial stress. J Neuro Res. 2018; 96: 1388– 1397. https://doi.org/10.1002/jnr.24259 * Buades-Rotger, M., Engelke, C., Beyer, F. et al. Endogenous testosterone is associated with lower amygdala reactivity to angry faces and reduced aggressive behavior in healthy young women. Sci Rep 6, 38538 (2016). https://doi.org/10.1038/srep38538 Ando, Sebastiano, et al. "Breast cancer: from estrogen to androgen receptor." Molecular and cellular endocrinology193.1-2 (2002): 121-128. Somboonporn, Woraluk, and Susan R. Davis. "Testosterone effects on the breast: implications for testosterone therapy for women." Endocrine reviews 25.3 (2004): 374-388. Donovitz, Gary, and Mandy Cotten. "Breast cancer incidence reduction in women treated with subcutaneous testosterone: testosterone therapy and breast cancer incidence study." European journal of breast health 17.2 (2021): 150. Glaser, Rebecca L., Anne E. York, and Constantine Dimitrakakis. "Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study." BMC cancer 19.1 (2019): 1271.   Thank you for tuning in and don't forget to hit that SUBSCRIBE button! Let us know in the COMMENTS if you have any questions or what you may want Dr. McCarthy to talk about next!   Check out Dr. Brendan McCarthy's Book! https://www.amazon.com/Jump-Off-Mood-...   -More Links- Instagram: www.instagram.com/drbrendanmccarthy TikTok: www.tiktok.com/drbrendanmccarthy Clinic Website: www.protealife.com

Drs. Jensen and Richey welcome Dr. Nicole Brouyette to Dean's Chat! Dr. Brouyette currently serves as the Associate Program director for Henry Ford Health System Residency program in Detroit MI. She got her undergraduate degree at Wayne State University with a Bachelors of Science in Molecular biology. She completed her Doctorate of Podiatric Medicine with the Ohio College and completed her 3 yr surgical residency training program with St. Johns Hospital and Medical center in Detroit MI. Join us as we discuss “all things podiatric medicine and surgery!”  This episode is sponsored by Bako Diagnostics! Dr. Brouyette is a true leader in the profession. Tune in for our discussion about her role as Associate program director and the overall structure and flow of the Henry Ford Health System Residency program. She also leans in and shares her experiences starting the Paragon28 Women in Podiatric Surgery Summit. Dr. Brouyette discusses the importance of female mentorship and some of the barriers young women face in medicine as they try to juggle the various roles they wish to pursue. She speaks openly and honestly about the challenges of being a woman in healthcare and how sometimes our own expectations can add additional stress in our lives. The discussion is uplifting, vulnerable and authentic as we discuss residency training, motherhood, maternity leave, feeling the need to fit into group and the power and freedom of living an authentic life.   Her career has been built on excellence. She has served in numersou leadership roles including ACFAS Great Lakes region Vice President, Member of the ACFAS Education and Scientific affairs committee, and faculty for AO NOrth America. She serves as section editor for the Journal of Foot and Ankle Surgery, NBPME Joint review panel for practitioners Part1 and has published a myriad of journal articles, poster presentations and invited lectures to various educational symposiums. We hope you enjoy this episode!    https://bmef.org/  https://paragon28meded.com/weekend-dpm-2024/vital-voices-womens-summit  https://www.abfas.org/residents  https://www.acfas.org/  https://www.aofoundation.org/aona     

En este capítulo, revisamos las diferentes estrategias para optimizar el soporte respiratorio en recién nacidos. En este episodio nos acompañan las neonatólogas Ana Ruth Mejia Elizondo y Victoria Lima Rogel. La Dra. Ana Ruth Mejia Elizondo es egresada de la Universidad Autónoma de San Luis Potosí donde obtuvo su título médico y posteriormente su posgrado en pediatría y neonatología. Actualmente es médico adscrito y jefe de servicio de Neonatología en el Hospital Central Dr. Ignacio Morones Prieto además de ser profesora de postgrado de pediatría y neonatología en la Universidad Autónoma de San Luis Potosí. La Dra. Victoria Lima Rogel es egresada de la Universidad Autónoma de San Luis Potosí. Posteriormente se especializó en Pediatría y Neonatología en la Universidad Nacional Autónoma de México. Cursó una Maestría en Ciencias en Biología Molecular en el Instituto Potosino de Investigación Científica y Tecnológica A.C. Actualmente es médico adscrito en el Hospital Central Dr. Ignacio Morones Prieto. Tiene una amplia currícula, tanto en instituciones del servicio público, como en la medicina privada, así como en campos de la ciencia y la investigación médica.Este podcast es patrocinado por Fisher & Paykel Healthcare. Bienvenidos a La Incubadora: una conversación sobre neonatología y medicina basada en evidencia. Nuestros episodios ofrecen la dosis ideal (en mg/kg) de los más recientes avances para el neonato y para las increíbles personas que forman parte de la medicina neonatal. Soy tu host, Maria Flores Cordova, MD. Este podcast está presentado por los médicos neonatólogos Dani de Luis Rosell, Elena Itriago, Carolina Michel y Juliana Castellanos. No dudes en enviarnos preguntas, comentarios o sugerencias a nuestro correo electrónico: nicupodcast@gmail.comSíguenos en nuestras redes:Twitter: @incubadorapodInstagram: @laincubadorapodcast Creado originalmente por Ben Courchia MD y Daphna Yasova Barbeau MD http://www.the-incubator.org

Garrett Butler, MD. Husband, father, son, friend, and family doc in rural WV. Undergraduate in Physics from Johns Hopkins University. Undergraduate in Molecular and Cell Biology from Towson University. MD from West Virginia University School of Medicine. Family Medicine residency at WVU SOM. Hospitalist at Vandalia Health Davis Medical Center. Outpatient family physician at Vandalia Health Broaddus Family Care. Hospitalist at Vandalia Health Broaddus Hospital. Medical director of Mansfield Place nursing home. Work With Us: Arétē by RAPID Health Optimization Links: Dr. Garrett Butler - Old Fellow Manor Anders Varner on Instagram Doug Larson on Instagram Coach Travis Mash on Instagram

A gente cresce ouvindo que ter filho é algo natural. Que basta querer — e pronto, acontece. Mas quem já passou pela jornada de tentar engravidar sabe que, muitas vezes, a realidade é bem mais complexa. Hoje, o Brasil tem uma taxa de fecundidade de apenas 1,57 filhos por mulher — a mais baixa da nossa história, bem abaixo do nível de reposição populacional. E isso não é só escolha: também é contexto. Mais mulheres estão deixando pra engravidar depois dos 30. Só que o corpo nem sempre acompanha esse novo tempo. A idade média da mulher ao ter o primeiro filho já passou dos 30 anos nas grandes capitais. E, ao mesmo tempo, cerca de 8 milhões de brasileiros enfrentam algum tipo de infertilidade. E aqui começa a via sacra: o peso da decisão, os exames, os custos, as tentativas frustradas. A gente fala em liberdade reprodutiva, mas essa liberdade ainda é muito restrita. Porque escolher ter um filho, adiar ou não ter envolve custo emocional, financeiro, físico — e quase sempre, é a mulher quem arca com tudo isso. Hoje, o Mamilos abre espaço pra falar com honestidade sobre a experiência de ser tentante. Sobre o corpo, a cabeça e o coração. Então puxa o banquinho, vem com a gente! Participam com a gente: Natália Gonçalves: Doutora em Biologia Celular e Molecular pela USP e head de Reprodução Humana da Dasa. Aline Borges de Araújo: Psicóloga especialista em Psicologia Clínica e Psicossomática, com foco em infertilidade e maternidade, ex-responsável pelo atendimento psicológico em Reprodução Humana da Unifesp. Anuncie no Mamilos ou contrate a consultoria Milos: mamilos@mamilos.me Saiba mais em Mamilos.me

Hola :)En el episodio de hoy vuelvo a traer a un VIP del podcast: mi padre, el doctor y catedrático de Bioquímica y Biología Molecular, Juan Viña, para explicarnos todo sobre la grasa corporal.En el podcast aprenderemos:Tipos de grasa que tenemos: blanca, parda y beige.Tipos de grasa blanca: diferencias regionales e implicaciones para la salud de tener la grasa blanca en la zona subcutánea (abdominal y femoral-glútea), en la zona visceral (epicárdica, retroperitoneal e intraperitoneal), o tenerla en zonas ectópicas (la que produce daño orgánico y se encuentra en el hígado, corazón, músculo y páncreas).¿Cómo valoramos la cantidad de grasa de forma sencilla?Hablaremos de las limitaciones del IMC y de otras alternativas mejores.Cómo valoramos la distribución de la grasa.Papel del exceso de insulina en el acúmulo de grasa visceral y ectópica.Qué tipos de fenotipos almacenadores de grasa existen.Implicaciones para la salud de la mala distribución de grasas.Para mas información ya sabéis que me tenéis en mi instagram @isabelvina dónde te comparto contenido diario  Mi TikTok @isabelvinabas En mi canal de YouTube https://www.youtube.com/channel/UC-dfdxLBcvfztBvRAKZSXGQ Y los suplementos formulados por mi https://ivbwellness.com

The asteroid Vesta may be a fragment of a much larger protoplanet, and astronomers examine old data to discover a large molecular cloud lurking right in the solar system's backyard. Get all the details, plus habitable exoplanets get another look, space news, and trivial matters with your friendly neighborhood astroquarks.

Sponsor Details:Insta360 X5 Camera. To bag a free invisible selfie stick worth US$24.99 with your purchase, head to store.insta360.com and use the promo code "spacetime", available for the first 30 standard package purchases only.This episode of SpaceTime explores fascinating new discoveries and urgent updates from the cosmos.First, astronomers have identified a vast molecular gas and dust cloud named Eos, located just 300 light years away from Earth. This remarkable finding, published in the journal Nature Astronomy, marks the first detection of a molecular cloud using far ultraviolet emissions of molecular hydrogen. Eos, which is composed primarily of hydrogen, presents unique opportunities for studying the interstellar medium and the processes of star formation. We discuss the implications of this discovery and how it could reshape our understanding of molecular clouds across the galaxy.Jupiter's Polar Cyclones Under the MicroscopeNext, we delve into the latest revelations from NASA's Juno mission, which is providing new insights into Jupiter's ferocious polar cyclones and the volcanic activity on its moon Io. With fresh observations, scientists are uncovering the dynamics of Jupiter's atmosphere and the subsurface temperature profile of Io, shedding light on the gas giant's extreme weather patterns and the moon's geological activity.Out of Control Russian SpacecraftFinally, we discuss the impending re-entry of the Venera 8 spacecraft, a remnant of the Soviet era, which is expected to crash back to Earth on May 10. Launched in 1972, this spacecraft has been tumbling in low Earth orbit for over five decades. We examine the risks associated with its uncontrolled descent and the potential impact it may have upon re-entry.www.spacetimewithstuartgary.com✍️ Episode ReferencesNature Astronomyhttps://www.nature.com/natureastronomy/NASA Juno Missionhttps://www.nasa.gov/mission_pages/juno/main/index.htmlBecome a supporter of this podcast: https://www.spreaker.com/podcast/spacetime-space-astronomy--2458531/support.00:00 This is space Time Series 28, episode 54 for broadcast on the 5th May, 202500:48 Astronomers have discovered a vast invisible molecular, gas and dust cloud near Earth12:40 Two key experiments are needed to help us understand the origin of Jupiter15:42 A failed Soviet spacecraft designed to land on Venus is about to crash on Earth19:00 New study claims people who use cannabis have higher risk of heart attack21:12 New study claims ghost lanterns in South Carolina may be caused by earthquakes